First Horizon Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.09M | Buy |
15,417
+103
| +0.7% | +$57.5K | 0.21% | 127 |
|
|
2025
Q1 | $9.71M | Buy |
15,314
+2,119
| +16% | +$1.46M | 0.27% | 114 |
|
|
2024
Q4 | $9.4M | Sell |
13,195
-242
| -2% | -$203K | 0.26% | 114 |
|
|
2024
Q3 | $14.1M | Sell |
13,437
-206
| -2% | -$229K | 0.39% | 82 |
|
|
2024
Q2 | $14.3M | Sell |
13,643
-438
| -3% | -$425K | 0.44% | 76 |
|
|
2024
Q1 | $13.6M | Sell |
14,081
-434
| -3% | -$413K | 0.42% | 80 |
|
|
2023
Q4 | $12.7M | Buy |
14,515
+608
| +4% | +$501K | 0.42% | 77 |
|
|
2023
Q3 | $11.4M | Buy |
13,907
+99
| +0.7% | +$77.8K | 0.41% | 80 |
|
|
2023
Q2 | $9.92M | Buy |
13,808
+178
| +1% | +$137K | 0.34% | 93 |
|
|
2023
Q1 | $11.2M | Buy |
13,630
+897
| +7% | +$677K | 0.4% | 80 |
|
|
2022
Q4 | $9.19M | Buy |
12,733
+557
| +5% | +$411K | 0.34% | 92 |
|
|
2022
Q3 | $8.39M | Buy |
12,176
+1,070
| +10% | +$673K | 0.34% | 93 |
|
|
2022
Q2 | $6.56M | Buy |
11,106
+7,978
| +255% | +$5.19M | 0.23% | 120 |
|
|
2022
Q1 | $2.19M | Buy |
3,128
+1,966
| +169% | +$1.24M | 0.12% | 180 |
|
|
2021
Q4 | $733K | Buy |
1,162
+297
| +34% | +$183K | 0.02% | 300 |
|
|
2021
Q3 | $524K | Buy |
865
+378
| +78% | +$235K | 0.02% | 332 |
|
|
2021
Q2 | $272K | Sell |
487
-13
| -3% | -$6.59K | 0.01% | 360 |
|
|
2021
Q1 | $236K | Buy |
500
+21
| +4% | +$10.2K | 0.01% | 354 |
|
|
2020
Q4 | $231K | Sell |
479
-152
| -24% | -$82K | 0.02% | 311 |
|
|
2020
Q3 | $353K | Sell |
631
-1
| -0.2% | -$606 | 0.03% | 243 |
|
|
2020
Q2 | $394K | Sell |
632
-6
| -0.9% | -$3.41K | 0.03% | 222 |
|
|
2020
Q1 | $311K | Buy |
638
+8
| +1% | +$3.3K | 0.03% | 231 |
|
|
2019
Q4 | $237K | Hold |
630
| – | – | 0.02% | 314 |
|
|
2019
Q3 | $175K | Hold |
630
| – | – | 0.01% | 347 |
|
|
2019
Q2 | $197K | Sell |
630
-80
| -11% | -$26.6K | 0.02% | 343 |
|
|
2019
Q1 | $292K | Hold |
710
| – | – | 0.02% | 293 |
|
|
2018
Q4 | $265K | Sell |
710
-1
| -0.1% | -$366 | 0.02% | 290 |
|
|
2018
Q3 | $287K | Buy |
711
+31
| +5% | +$11.8K | 0.02% | 313 |
|
|
2018
Q2 | $235K | Buy |
680
+630
| +1,260% | +$197K | 0.02% | 343 |
|
|
2018
Q1 | $16K | Sell |
50
-126
| -72% | -$43.8K | ﹤0.01% | 861 |
|
|
2017
Q4 | $66K | Buy |
176
+34
| +24% | +$13.8K | 0.01% | 472 |
|
|
2017
Q3 | $63K | Sell |
142
-24
| -14% | -$11.4K | 0.01% | 460 |
|
|
2017
Q2 | $82K | Buy |
166
+44
| +36% | +$19.3K | 0.01% | 413 |
|
|
2017
Q1 | $47K | Buy |
122
+69
| +130% | +$25.6K | 0.01% | 545 |
|
|
2016
Q4 | $21K | Hold |
53
| – | – | ﹤0.01% | 777 |
|
|
2016
Q3 | $21K | Buy |
53
+17
| +47% | +$6.82K | ﹤0.01% | 771 |
|
|
2016
Q2 | $13K | Hold |
36
| – | – | ﹤0.01% | 879 |
|
|
2016
Q1 | $13K | Hold |
36
| – | – | ﹤0.01% | 927 |
|
|
2015
Q4 | $20K | Sell |
36
-2
| -5% | -$1.08K | ﹤0.01% | 730 |
|
|
2015
Q3 | $17K | Sell |
38
-19
| -33% | -$10.2K | ﹤0.01% | 850 |
|
|
2015
Q2 | $29K | Sell |
57
-41
| -42% | -$20K | ﹤0.01% | 719 |
|
|
2015
Q1 | $43K | Sell |
98
-15
| -13% | -$6.36K | 0.01% | 592 |
|
|
2014
Q4 | $46K | Buy |
113
+1
| +0.9% | +$393 | 0.01% | 568 |
|
|
2014
Q3 | $40K | Sell |
112
-15
| -12% | -$5.03K | 0.01% | 590 |
|
|
2014
Q2 | $36K | Buy |
127
+26
| +26% | +$7.71K | 0.01% | 645 |
|
|
2014
Q1 | $30K | Buy |
101
+37
| +58% | +$11.4K | ﹤0.01% | 656 |
|
|
2013
Q4 | $18K | Buy |
+64
| New | +$18.4K | ﹤0.01% | 770 |
|
|
2013
Q3 | – | Sell |
-18
| Closed | -$4K | – | 1181 |
|
|
2013
Q2 | $4K | Buy |
+18
| New | +$4.19K | ﹤0.01% | 729 |
|
Other funds holding REGN
First Horizon Advisors's REGN Position: Q2 2025 in Review
First Horizon Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.67% in Q2 2025, buying an estimated $57.5K and bringing the position to 15,417 shares worth $8.09M. The position accounts for 0.21% of the portfolio, ranked #127.
First Horizon Advisors first reported a position in REGN in Q2 2013 and has held it in 48 quarters since. The position peaked at $14.3M in Q2 2024. 1,203 funds tracked by Wall St. Rank hold REGN as of Q2 2025.
- First Horizon Advisors held 15,417 shares of Regeneron Pharmaceuticals worth $8.09M as of Q2 2025.
- First Horizon Advisors bought 103 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $57.5K.
- Regeneron Pharmaceuticals made up 0.21% of First Horizon Advisors's portfolio in Q2 2025, its #127 holding.
- First Horizon Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
- First Horizon Advisors's Regeneron Pharmaceuticals position peaked at $14.3M in Q2 2024.
- 1,203 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.
Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.